REGENXBIO (RGNX) Stock Soars On Encouraging Trial Efficacy Data
After receiving favorable data regarding the efficacy of its clinical research, REGENXBIO Inc. (NASDAQ: RGNX) witnessed a significant gain in value, with its shares soaring by 15.17% to $24.60. RGNX today reported early findings from the Phase I/II AFFINITY DUCHENNE research of RGX-202, a potential treatment for Duchenne muscular dystrophy (Duchenne), in children ages 4 […]
